^
    5ms
    Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov)
    P1, N=30, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    8ms
    A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    9ms
    Selectivity and anti-tumor immune elevation by vascular-targeted photodynamic therapy of mouse orthotopic bladder cancer model. (PubMed, Photochem Photobiol)
    Vascular-targeted photodynamic therapy (VTP) with WST11 is a non-surgical tumor ablation approach that is currently being tested in a phase 3 clinical trial for the treatment of upper tract urothelial cancer...Moreover, VTP therapy prolonged the survival of mice bearing orthotopic tumors compared with the untreated control. These results suggest that VTP can selectively ablate malignant tumors in the bladder and promote a robust anti-tumor response in a mouse model that can further augment the therapeutic outcome.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ITGAM (Integrin, alpha M)
    |
    Tookad (padeliporfin)
    10ms
    ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date
    |
    Tookad (padeliporfin)
    12ms
    CLIN1601 PCM204t: Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Steba Biotech S.A. | Trial completion date: Nov 2024 --> Feb 2025
    Trial completion date • HEOR
    |
    Tookad (padeliporfin)
    12ms
    Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Tookad (padeliporfin)
    1year
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Recruiting, Impact Biotech Ltd | Suspended --> Recruiting
    Enrollment open
    |
    Tookad (padeliporfin)
    1year
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Suspended, Impact Biotech Ltd | Trial completion date: Dec 2027 --> Dec 2028 | Not yet recruiting --> Suspended | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    Tookad (padeliporfin)
    over1year
    Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Impact Biotech Ltd | Active, not recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Tookad (padeliporfin)
    over1year
    Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Impact Biotech Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tookad (padeliporfin)
    over1year
    UCM301: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    Tookad (padeliporfin)
    almost2years
    Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Impact Biotech Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Tookad (padeliporfin)